Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborators:
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Information provided by:
Baker Heart Research Institute
ClinicalTrials.gov Identifier:
NCT00168519
First received: September 14, 2005
Last updated: December 14, 2009
Last verified: December 2009
  Purpose

The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.


Condition Intervention
Diabetes Mellitus, Type 2
Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Baker Heart Research Institute:

Primary Outcome Measures:
  • glucose metabolism [ Time Frame: 3 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: October 2002
Study Completion Date: April 2009
Arms Assigned Interventions
Active Comparator: 1 Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Sodium Nitroprusside - one 30 minute intravenous infusion

Pentalong - two tablets orally (total 160mg)

Imdur - two tablets orally (total 120mg)


  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patients with type 2 diabetes

  • Non-smokers
  • Free of overt coronary disease (stress ECG)
  • Body mass index < 35 kg.m-2
  • Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • Unmedicated (diet controlled)

Healthy controls

  • Non-smokers
  • Free of overt coronary disease (ECG)
  • Body mass index < 30 kg.m-2
  • Fasting plasma glucose < 6.1 mmol.L-1
  • Unmedicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168519

Locations
Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 8008
Sponsors and Collaborators
Baker Heart Research Institute
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00168519     History of Changes
Other Study ID Numbers: 51/02
Study First Received: September 14, 2005
Last Updated: December 14, 2009
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Baker Heart Research Institute:
Diabetes Mellitus, Type 2
Blood Glucose
Exercise
Muscle Contraction
Nitric Oxide
Nitrates

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Verapamil
Nitroprusside
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Nitric Oxide Donors
Antihypertensive Agents

ClinicalTrials.gov processed this record on July 29, 2014